Koers Arch Biopartners Inc. Other OTC
Aandelen
ACHFF
CA03938C1041
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 2 mln. 1,45 mln. 1,35 mln. | Omzet 2025 * | 2 mln. 1,45 mln. 1,35 mln. | Marktkapitalisatie | 111 mln. 80,34 mln. 74,44 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 55,3 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 55,3 x |
K/w-verhouding 2024 * |
-24,8
x | K/w-verhouding 2025 * |
-24,8
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 80,29% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Daniel Muruve
FOU | Founder | - | 04-03-83 |
Richard Muruve
FOU | Founder | - | 04-03-83 |
Andrew Bishop
DFI | Director of Finance/CFO | 58 | 01-04-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Richard Rossman
BRD | Director/Board Member | - | 07-05-10 |
Richard Muruve
FOU | Founder | - | 04-03-83 |
Claude Allary
BRD | Director/Board Member | 69 | 01-04-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+51,85% | 57,87 mld. | |
+41,42% | 40,25 mld. | |
-5,25% | 39,94 mld. | |
-5,16% | 28,54 mld. | |
+12,79% | 26,4 mld. | |
-20,18% | 19,33 mld. | |
+30,88% | 12,4 mld. | |
+0,61% | 12,23 mld. | |
+25,06% | 12,2 mld. |